Supplements

Introduction

August 2018 Br J Cardiol 2018;25(suppl 1):S3–S5

Introduction

Patients with atrial fibrillation are at an increased risk for ischaemic stroke and require long-term prophylaxis with an anticoagulant. Ablation and direct current cardioversion are...
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

August 2018 Br J Cardiol 2018;25(suppl 1):S6–S11

Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI

The PIONEER AF-PCI trial was an open-label, randomised, controlled, multi-centre trial that evaluated the safety of two different regimens of rivaroxaban compared with vitamin K...
The PIONEER AF-PCI study: its implications for everyday practice in the UK

August 2018 Br J Cardiol 2018;25(suppl 1):S12–S15

The PIONEER AF-PCI study: its implications for everyday practice in the UK

Our ageing population is resulting in increasing rates of coronary artery disease and atrial fibrillation (AF), which require intervention. Anticoagulation in patients with non-valvular AF...
The potential for NOACs in cardiac ablation in the UK

August 2018 Br J Cardiol 2018;25(suppl 1):S16–S17

The potential for NOACs in cardiac ablation in the UK

The procedural and post-procedure risk of stroke associated with catheter ablation of atrial fibrillation (AF), even in patients with low CHA2DS2-VASc scores, highlight the need...
Use of NOAC drugs in DC cardioversion for patients with non-valvular AF

August 2018 Br J Cardiol 2018;25(suppl 1):S18–S20

Use of NOAC drugs in DC cardioversion for patients with non-valvular AF

Direct current cardioversion (DCCV) is a frequently used and effective strategy for the restoration of sinus rhythm in patients with atrial fibrillation (AF). Anticoagulation for...

September 2017 Br J Cardiol 2017;24(suppl 1):S2

Optimising the management of post ACS patients: Introduction

In this supplement we bring together four highly respected cardiology authors who provide an up-to-date analysis of the current management of the post-acute coronary syndrome...
Acute coronary syndrome in adults: scope of the problem in the UK

September 2017 Br J Cardiol 2017;24(suppl 1):S3–S9

Acute coronary syndrome in adults: scope of the problem in the UK

Click here to take a CPD test on this article Acute coronary syndrome (ACS) accounts for a substantial number of admissions to UK hospitals. As a...
Dual antiplatelet therapy following acute coronary syndromes: optimal regimens and duration of therapy

September 2017 Br J Cardiol 2017;24(suppl 1):S10–S15

Dual antiplatelet therapy following acute coronary syndromes: optimal regimens and duration of therapy

Click here to take a CPD test on this article Dual antiplatelet therapy (DAPT) post-acute coronary syndrome (ACS) is well established. Currently, three oral P2Y12 inhibitors...
The post-ACS patient: shared care to improve outcomes

September 2017 Br J Cardiol 2017;24(suppl 1):S16–S20

The post-ACS patient: shared care to improve outcomes

Click here to take a CPD test on this article The acute care of patients following myocardial infarction has progressed steadily over the past 29 years...
Introduction

November 2016 Br J Cardiol 2016;23(suppl 2):S1–S12

Introduction

Multiple clinical risk factors, electrocardiographic/echocardiographic features and biochemical markers are associated with an increased risk of atrial fibrillation (AF). AF poses a significant challenge from...
Direct current cardioversion and thromboprophylaxis in atrial fibrillation

November 2016 Br J Cardiol 2016;23(suppl 2):S1–S12

Direct current cardioversion and thromboprophylaxis in atrial fibrillation

Atrial fibrillation (AF) is the most common type of sustained cardiac arrhythmia, with an overall prevalence in the UK of 1.6% in women and 2.4%...
Introduction

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Introduction

Heart failure is a leading cause of morbidity and mortality and presents many treatment challenges. Its prognosis is poor yet many patients do not receive...
Neurohumoral activation in heart failure and the implications for treatment

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Neurohumoral activation in heart failure and the implications for treatment

The pathophysiology of heart failure is complex. This article describes the neurohumoral pathways that are active in chronic heart failure with left ventricular systolic dysfunction...
Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

PARADIGM-HF was the first study to compare the long-term efficacy and safety of the angiotensin-receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan (previously known as LCZ696), against standard care...
The use of sacubitril/valsartan (LCZ696) in clinical practice

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

The use of sacubitril/valsartan (LCZ696) in clinical practice

Professor John McMurray, the principal investigator in the PARADIGM-HF study, writes about his experience with sacubitril/valsartan (known as LCZ696 at the time of the study)...
A comment from primary care

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

A comment from primary care

Much of the work in reducing the mortality and morbidity from heart failure will be carried out in primary care. Treatment of these patients with...
Pulmonary hypertension in UK clinical practice: an update

May 2015 Br J Cardiol 2015;22(suppl 1):S2–S15

Pulmonary hypertension in UK clinical practice: an update

Insights from the world of cardiology...
Unlocking the potential of NOACs

December 2014 Br J Cardiol 2014;21(suppl 2):S1–S7

Unlocking the potential of NOACs

Insights from the world of cardiology...
Rivaroxaban in non-valvular AF – UK experience in perspective

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Rivaroxaban in non-valvular AF – UK experience in perspective

Insights from the world of cardiology...
Rivaroxaban in non-valvular AF – French experience in perspective

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Rivaroxaban in non-valvular AF – French experience in perspective

Insights from the world of cardiology...